Skip to main content
SpringerLink
Log in
Book cover

Textbook of Personalized Medicine pp 165–254Cite as

Personalized Therapy for Cancer

  • Chapter
  • First Online:

  • 1522 Accesses

Abstract

Management of cancer has been unsatisfactory in the past but an understanding of the molecular, genetic and genomic aspects of cancer started to accelerate progress in cancer therapy (Jain 2005). Several comprehensive studies have demonstrated the utility of gene expression profiles for the classification of tumors into clinically relevant subtypes and the prediction of clinical outcomes. The role of oncoproteomics in the personalized management of cancer was first emphasized in 2004 (Jain 2004). Considerable progress has been made in this field during the past few years. Other factors that drive the development of personalized therapy for cancer are listed in Table 10.1. The preceding chapter described how cancer cell therapy and cancer vaccines can be personalized. Information presented in this chapter describes personalization of other cancer therapies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Acharya CR, Hsu DS, Anders CK et al (2008) Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299:1574–1587

    CAS  PubMed  Google Scholar 

  • Agadjanian H, Ma J, Rentsendorj A et al (2009) Tumor detection and elimination by a targeted gallium corrole. Proc Natl Acad Sci USA 106:6105–6110

    CAS  PubMed  Google Scholar 

  • Alvero AB, Chen R, Fu HH et al (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8:158–166

    CAS  PubMed  Google Scholar 

  • Anderson AR, Weaver AM, Cummings PT, Quaranta V (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127:905–915

    CAS  PubMed  Google Scholar 

  • Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357–365

    CAS  PubMed  Google Scholar 

  • Beier D, Röhrl S, Pillai DR et al (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68:5706–5715

    CAS  PubMed  Google Scholar 

  • Ben-Haim S, Ell P (2009) 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 50:88–99

    PubMed  Google Scholar 

  • Bild AH, Yao G, Chang JT et al (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357

    CAS  PubMed  Google Scholar 

  • Bosco EE, Wang Y, Xu H et al (2007) The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 117:218–228

    CAS  PubMed  Google Scholar 

  • Boyer J, Allen WL, McLean EG et al (2006) Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66:2765–2777

    Google Scholar 

  • Brower SL, Fensterer JE, Bush JE (2008) The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol 414:57–78

    CAS  PubMed  Google Scholar 

  • Burgess DJ, Doles J, Zender L et al (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 105:9053–9058

    PubMed  Google Scholar 

  • Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192

    CAS  PubMed  Google Scholar 

  • Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502

    CAS  PubMed  Google Scholar 

  • Carrasco DR, Tonon G, Huang Y et al (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313–325

    CAS  PubMed  Google Scholar 

  • Carter SL, Eklund AC, Kohane IS et al (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043–1048

    CAS  PubMed  Google Scholar 

  • Chaurand P, Sanders ME, Jensen RA, Caprioli RM (2004) Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 165:1057–1068

    CAS  PubMed  Google Scholar 

  • Chen HY, Yu SL, Chen CH et al (2007) A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer. NEJM 356:11–20

    Google Scholar 

  • Cunningham L, Aplenc R (2007) Pharmacogenetics of acute lymphoblastic leukemia treatment response. Expert Opin Pharmacother 8:2519–2531

    CAS  PubMed  Google Scholar 

  • de la Iglesia N, Konopka G, Puram SV et al (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22:449–462

    PubMed  Google Scholar 

  • Diehn M, Nardini C, Wang DS et al (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA 105: 5213–5218

    CAS  PubMed  Google Scholar 

  • El-Deiry WS, Sigman CC, Kelloff GJ (2006) Imaging and oncologic drug development. J Clin Oncol 24:3261–3273

    CAS  PubMed  Google Scholar 

  • Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388

    CAS  PubMed  Google Scholar 

  • Endo K, Sasaki H, Yano M et al (2006) Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep 16:533–541

    CAS  PubMed  Google Scholar 

  • Fogli S, Caraglia M (2009) Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. Expert Opin Pharmacother 10:1095–1108

    CAS  PubMed  Google Scholar 

  • Freedman AN, Slattery ML, Ballard-Barbash R et al (2009) A colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 27:686–693.

    Google Scholar 

  • Fry RJ, Svensson JP, Valiathan C et al (2008) Genomic predictors of interindividual differences in response to DNA damaging agents. Genes Dev 22:2621–2626

    CAS  PubMed  Google Scholar 

  • Garman KS, Acharya CR, Edelman E et al (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 105:19431–19437

    Google Scholar 

  • Giotopoulos G, Symonds RP, Foweraker K et al (2007) The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 96:1001–1007

    CAS  PubMed  Google Scholar 

  • Glas AM, Floore A, Delahaye LJ et al (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7(1):278.

    PubMed  Google Scholar 

  • Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318

    CAS  PubMed  Google Scholar 

  • Gong Y, Yan K, Lin F et al (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203–211

    CAS  PubMed  Google Scholar 

  • Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    CAS  PubMed  Google Scholar 

  • Hirsch FR, Witta S (2005) Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 17:118–122

    CAS  PubMed  Google Scholar 

  • Holdenrieder S, Stieber P, von Pawel J et al (2004) Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 10:5981–5987.

    CAS  PubMed  Google Scholar 

  • Huang RS, Duan S, Bleibel WK et al (2007) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 104:9758–9763

    CAS  PubMed  Google Scholar 

  • Idbaih A, Marie Y, Pierron G et al (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483–487

    CAS  PubMed  Google Scholar 

  • Inoges S, Rodriguez-Calvillo M, Zabalegui N et al (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98:1292–1301

    PubMed  Google Scholar 

  • Iwadate Y, Sakaida T, Saegusa T et al (2005) Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol 26:993–998

    CAS  PubMed  Google Scholar 

  • Jain KK (2004) Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics 1:49–55

    CAS  PubMed  Google Scholar 

  • Jain KK (2005) Personalised medicine for cancer – from drug development into clinical practice. Exp Opin Pharmacother 6:1463–1476

    CAS  Google Scholar 

  • Jain KK (2009k) Molecular diagnosis of brain tumors. In: Gilman S (ed) Medlink neurology, Medlink Corporation, San Diego, CA.

    Google Scholar 

  • Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S et al (2005) Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther 12:699–707

    CAS  PubMed  Google Scholar 

  • Jeuken JWM, van der Maazen RWM, Wesseling P (2006) Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Technol Cancer Res Treat 5:215–229

    CAS  PubMed  Google Scholar 

  • Juhász C, Muzik O, Lu X et al (2009) Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med 50:356–363

    PubMed  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    CAS  PubMed  Google Scholar 

  • Kimura H, Kasahara K, Kawaishi M et al (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915–3921

    Google Scholar 

  • Korpanty G, Carbon JG, Grayburn PA et al (2007) Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 13:323–330

    CAS  PubMed  Google Scholar 

  • Kretschmar C, Kleinberg L, Greenberg M et al (2007) Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 48:285–291

    CAS  PubMed  Google Scholar 

  • Labuhn M, Vuaroqueaux V, Fina F et al (2006) Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers 21:30–39

    CAS  PubMed  Google Scholar 

  • Laing RE, Walter MA, Campbell DO et al (2009) Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci USA 106:2847–2852

    CAS  PubMed  Google Scholar 

  • Lapointe J, Li C, Higgins JP et al (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811–816

    CAS  PubMed  Google Scholar 

  • Leary RJ, Lin JC, Cummins J et al (2008) Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105:16224–16229

    CAS  PubMed  Google Scholar 

  • Lee E, Nichols P, Spicer D et al (2006) GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66:7849–7853

    CAS  PubMed  Google Scholar 

  • Leong C, Vidnovic N, DeYoung MP et al (2007) The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117:1370–1380

    CAS  PubMed  Google Scholar 

  • Liang Y, Diehn M, Watson N et al (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102:5814–5819

    CAS  PubMed  Google Scholar 

  • Liu R, Wang X, Chen GY et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217–226

    CAS  PubMed  Google Scholar 

  • Lorenzi PL, Reinhold WC, Rudelius M et al (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 5:2613–2623

    CAS  PubMed  Google Scholar 

  • Lukes L, Crawford N, Walker R, Hunter KW (2009) The origins of breast cancer prognostic gene expression profiles. Cancer Res 69:310–318

    CAS  PubMed  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    CAS  PubMed  Google Scholar 

  • Ma XJ, Hilsenbeck SG, Wang W et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611–4619

    CAS  PubMed  Google Scholar 

  • Maheswaran S, Sequist LV, Nagrath S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366–377

    CAS  PubMed  Google Scholar 

  • Mandl SJ, Mari C, Edinger M et al (2004) Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 3:1–8

    Google Scholar 

  • Mannello F, Medda V, Tonti GA (2009) Protein profile ana lysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev Proteomics 6:43–60

    CAS  PubMed  Google Scholar 

  • Marcuello E, Altes A, Menoyo A et al (2006) Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 57:835–840

    CAS  PubMed  Google Scholar 

  • Martinez R, Schackert G, Esteller M (2007) Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol 82:133–139

    CAS  PubMed  Google Scholar 

  • Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    CAS  PubMed  Google Scholar 

  • Miller LD, Liu ET (2007) Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res 9:206.

    PubMed  Google Scholar 

  • Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102:5524–5529

    CAS  PubMed  Google Scholar 

  • Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971–2979

    CAS  PubMed  Google Scholar 

  • Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286

    CAS  PubMed  Google Scholar 

  • Mukohara T, Engelman JA, Hanna NH et al (2005) Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185–1194

    CAS  PubMed  Google Scholar 

  • Nagrath S, Sequist LV, Maheswaran S et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450:1235–1239

    CAS  PubMed  Google Scholar 

  • Nuyten DS, Kreike B, Hart AA et al (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62.

    PubMed  Google Scholar 

  • Ogino S, Nosho K, Kirkner GJ et al (2008) A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 100:1734–1738

    CAS  PubMed  Google Scholar 

  • Ornish D, Magbanua M, Weidner G et al (2008) Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA 105:8369–8374

    CAS  PubMed  Google Scholar 

  • Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    CAS  PubMed  Google Scholar 

  • Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826

    CAS  PubMed  Google Scholar 

  • Park S, Hatanpaa KJ, Xie Y et al (2009b) The receptor interacting protein 1 inhibits p53 induction through NF-{kappa}B activation and confers a worse prognosis in glioblastoma. Cancer Res 69:2809–2816

    CAS  Google Scholar 

  • Park Y, Freedman AN, Gail MH et al (2009a) Validation of a colorectal cancer risk prediction model among whites 50 years old and over. J Clin Oncol 27:694–698

    Google Scholar 

  • Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167

    PubMed  Google Scholar 

  • Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    CAS  PubMed  Google Scholar 

  • Petty RD, Kerr KM, Murray GI et al (2006) Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol 24:1729–1744

    CAS  PubMed  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    CAS  PubMed  Google Scholar 

  • Polo JM, Juszczynski P, Monti S et al (2007) Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 104:3207–3212

    CAS  PubMed  Google Scholar 

  • Potti A, Dressman HK, Bild A (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294–1300

    CAS  PubMed  Google Scholar 

  • Pritchard KI, Shepherd LE, O’Malley FP et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103–2111

    CAS  PubMed  Google Scholar 

  • Rieger KE, Hong WJ, Tusher VJ et al (2004) Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. Proc Natl Acad Sci USA 101:6635–6640

    CAS  PubMed  Google Scholar 

  • Rosell R, Cuello M, Cecere F et al (2006) Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 18:135–143

    PubMed  Google Scholar 

  • Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079–17084

    CAS  PubMed  Google Scholar 

  • Rouzier R, Rajan R, Wagner P et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320

    CAS  PubMed  Google Scholar 

  • Santana VM, Furman WL, Billups CA et al (2005) Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039–4047

    CAS  PubMed  Google Scholar 

  • Schmieder AH, Winter PM, Caruthers SD et al (2005) Molecular MR imaging of melanoma angiogenesis with anb3-targeted paramagnetic nanoparticles. Magnet Reson Med 53:621–627

    CAS  Google Scholar 

  • Schwartz SA, Weil RJ, Thompson RC et al (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65:7674–7681

    CAS  PubMed  Google Scholar 

  • Sequist LV, Nagrath S, Toner M et al (2009) The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 4:281–283

    PubMed  Google Scholar 

  • Serkova N, Boros LG (2005) Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am J Pharmacogenomics 5:293–302

    CAS  PubMed  Google Scholar 

  • Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274

    PubMed  Google Scholar 

  • Sohn JW, Lee SY, Lee SJ et al (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137–141

    PubMed  Google Scholar 

  • Song LL, Miele L (2007) Cancer stem cells--an old idea that’s new again: implications for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther 7:431–438

    Google Scholar 

  • Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800

    CAS  PubMed  Google Scholar 

  • Stamatakos GS, Antipas VP, Uzunoglu NK (2006) Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. Comput Biol Med 36:1216–1234

    CAS  PubMed  Google Scholar 

  • Stanulla M, Schaeffeler E, Flohr T et al (2005) Thiopurine methyltransferase (tpmt) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293:1485–1489

    CAS  PubMed  Google Scholar 

  • Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 103:11154–11159

    CAS  PubMed  Google Scholar 

  • Taguchi F, Solomon B, Gregorc V et al (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99:838–846

    CAS  PubMed  Google Scholar 

  • Teschendorff AE, Miremadi A, Pinder SE et al (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8:R157

    PubMed  Google Scholar 

  • Thomas G, Horvath S, Smith BL et al (2004) Antibody based profiling of the PI3K pathway in clinical prostate cancer. Clin Cancer Res 10:8351–8356

    CAS  PubMed  Google Scholar 

  • Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133–144

    CAS  PubMed  Google Scholar 

  • Visintin I, Feng Z, Longton G et al (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14:1065–1072

    CAS  PubMed  Google Scholar 

  • Wang W, Kim SH, El-Deiry WS (2006) Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. PNAS 103:11003–11008

    Google Scholar 

  • Watters JW, Kraja A, Meucci MA et al (2004) Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 101:11809–11814

    CAS  PubMed  Google Scholar 

  • Weber WA, Petersen V, Schmidt B et al (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657

    CAS  PubMed  Google Scholar 

  • Weichselbaum RR, Ishwaran H, Yoon T et al (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105:18490–18495

    CAS  PubMed  Google Scholar 

  • Weinstein JN (2006) Spotlight on molecular profiling: “integromic” analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 5:2601–2605

    CAS  PubMed  Google Scholar 

  • Wu X, Lu C, Chiang SS, Ajani JA (2005) Pharmacogenetics in esophageal cancer. Semin Oncol 32(6 Suppl 9):87–89

    Google Scholar 

  • Xing D, Orsulic S (2005) A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA 102: 6936–6941

    CAS  PubMed  Google Scholar 

  • Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017–1021

    Google Scholar 

  • Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808

    CAS  PubMed  Google Scholar 

  • Zhu H, Acquaviva J, Ramachandran P et al (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 106:2712–2716

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jain PharmaBiotech, Blaesiring 7, 4057, Basel, Switzerland

    Kewal K. Jain

Authors
  1. Kewal K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kewal K. Jain .

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jain, K.K. (2009). Personalized Therapy for Cancer. In: Textbook of Personalized Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0769-1_10

Download citation

Publish with us

Policies and ethics

Search

Navigation